# GLP-1 medicines and research materials

Canonical: https://europeanpeptideshop.com/blog/glp-1-peptides-vs-research-peptides/

Explore the catalogue and research library. Ordering and shipping have not opened yet.

Comparisons · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/)

### On this page

## “GLP-1” and “research peptide” describe different things

GLP-1 identifies glucagon-like peptide-1 and its associated receptor terminology. “Research peptide” describes a material's laboratory supply context. These are not mutually exclusive chemical categories: a peptide associated with GLP-1 receptor research is still a peptide. Neither label establishes the identity, specification or authorised use of a particular vial.

For a meaningful comparison, ask four questions separately: which molecule is named, which targets are studied, what evidence exists for that molecule, and what preparation is actually supplied. A broad category label cannot answer all four.

## One receptor family does not mean one compound

The receptor descriptions used for Semaglutide, Tirzepatide and Retatrutide are different. The [three-compound comparison](https://europeanpeptideshop.com/blog/retatrutide-vs-tirzepatide-vs-semaglutide/) sets out their identities and evidence boundaries. Describing a compound as dual- or triple-targeted is not a ranking of product quality or a claim that one can replace another.

Retatrutide's development identifier is LY3437943. The [original discovery report by Coskun and colleagues](https://pubmed.ncbi.nlm.nih.gov/35985340/) describes activity at GLP-1, GIP and glucagon receptors using defined experimental systems. The [phase 1b report by Urva and colleagues](https://pubmed.ncbi.nlm.nih.gov/36354040/) concerns a clinical-development preparation and a specified study population. Neither publication analyses a PCUK batch.

## Read the evidence at its actual level

Evidence | Question it may address

Chemical identity record | Which structure the name denotes

Receptor or cell assay | Behaviour in that experimental system

Animal study | Findings in the studied species and conditions

Human study | Findings in its participants with its study preparation

Batch analytical report | Identity, composition or purity of the tested sample by stated methods

Moving from one row to another requires additional evidence. A chromatogram does not establish a clinical outcome. A clinical paper does not establish the identity of a commercial vial. Even a shared compound name does not demonstrate equivalent formulation, manufacturing controls or analytical specification.

## Laboratory listings and finished medicines

A listed laboratory reagent is not a finished medicine. Product authorisation, where it exists, belongs to the particular medicine and its approved conditions. A research-use label does not transfer that authorisation to another preparation. PCUK's supplied materials remain restricted to non-clinical in-vitro laboratory research.

## What to compare on a product page

For [Retatrutide 10mg](https://europeanpeptideshop.com/shop/retatrutide-10mg/), [20mg](https://europeanpeptideshop.com/shop/retatrutide-20mg/) and [30mg](https://europeanpeptideshop.com/shop/retatrutide-30mg/), compare the labelled quantities, current availability and batch-document links. Quantity is a supplied format, not an administration instruction. Use the [Retatrutide identity reference](https://europeanpeptideshop.com/blog/retatrutide/) for nomenclature and the [COA guide](https://europeanpeptideshop.com/blog/how-to-read-peptide-coa/) to interpret the product's documentary evidence.

## EPS documentation

Use the [research catalogue](https://europeanpeptideshop.com/shop/) to check the exact name, labelled amount and format. The [COA library](https://europeanpeptideshop.com/coa/) publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch.

## Laboratory research only

Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here.

## References

- [original discovery report by Coskun and colleagues](https://pubmed.ncbi.nlm.nih.gov/35985340/)

- [phase 1b report by Urva and colleagues](https://pubmed.ncbi.nlm.nih.gov/36354040/)

## More articles

Compound research · 4 min read

## [GLP-1s, visceral fat and inflammation](https://europeanpeptideshop.com/blog/glp1-inflammation-visceral-fat/)

Understand visceral fat, liver fat, body weight and inflammation markers, and how to read GLP-1 study results without confusing those outcomes.

8 November 2026

Research news · 2 min read

## [Peptides and UK medicines law](https://europeanpeptideshop.com/blog/human-medicines-regulations-2012-peptides/)

The Human Medicines Regulations 2012 decide when a peptide counts as a medicine in the UK. What regulations 2 and 46 say, in plain English.

8 November 2026

Research news · 3 min read

## [The FDA's RonanRx GLP-1 warning](https://europeanpeptideshop.com/blog/fda-ronanrx-compounded-glp1-warning/)

Read the FDA’s RonanRx warning in context: compounded semaglutide and tirzepatide, approval claims, manufacturer identity and product-origin language.

8 November 2026